Our Pipeline | ImmunoGen for ADC Technology-focused Cancer Treatment

Our

Pipeline

We bring more than 35 years of innovation to the ADC field. Our lead program, mirvetuximab soravtansine, is a first-in-class ADC in Phase 3 development for platinum-resistant ovarian cancer and we have a number of ADCs in development in our clinical and early stage pipelines.

Clinical Pipeline

Compound

Preclinical

Phase 1

Phase 2

Phase 3

Mirvetuximab Soravtansine

TARGET: Folate receptor alpha (FRa)

Ovarian monotherapy

Ovarian with bevacizumab

Ovarian with pembrolizumab

Ovarian with carboplatin and bevacizumab

Ovarian with carboplatin

Ovarian with PLD

IMGN779

TARGET: CD33

Acute myeloid leukemia

IMGN632

TARGET: CD123

Hematologic malignancies

Solid Tumor Liquid Tumor

Early Stage Pipeline

Program

Discovery

Preclinical Research

Preclinical Development

ADAM9: MacroGenics Co-Development

ADAM9: MacroGenics Co-Development

cMet

cMet

EpCAM Probody Drug Conjugate

EpCAM Probody Drug Conjugate

Hematologic Malignancies

Hematologic Malignancies

Ovarian Next Generation

Ovarian Next Generation

Exploratory

Exploratory

Solid Tumor Liquid Tumor

partnerships

In addition to our own, proprietary pipeline of ADC candidates, we have a number of partnerships and collaborations in place that leverage our technology – and those of our collaborators – to address unmet medical needs. We are constantly seeking out innovative partnerships with the goal of advancing science, gaining access to complimentary capabilities, strengthening our financial position, and creating more value for ImmunoGen.

Examples of our partnerships include a strategic collaboration with CytomX Therapeutics to develop probody drug conjugate (PDC) therapies, and a strategic collaboration and option agreement with Jazz Pharmaceuticals to develop and commercialize hematology-related ADCs.

legacy platform deals

Our technology platform has been the basis for a number of high-value partnerships for the company, including the first-ever ADC approved as a treatment option for HER2-positive breast cancer, which is marketed by Roche, called Kadcyla®.

In addition to Roche, we have ADC technology deals in place with Amgen, Bayer, Biotest, Sanofi, and Takeda.